Italia markets closed

Dow Jones
38.616,64
+27,48(+0,07%)
Nasdaq
17.734,98
+46,10(+0,26%)
Nikkei 225
38.102,44
-712,12(-1,83%)
EUR/USD
1,0724
+0,0015(+0,14%)
Bitcoin EUR
60.828,55
-1.287,50(-2,07%)
CMC Crypto 200
1.371,43
-16,73(-1,21%)

NBIX Jul 2024 145.000 call

OPR - OPR Prezzo differito. Valuta in USD.

Aggiungi a watchlist

1,6500

+0,0800

(+5,10%)

In data: 09:30AM EDT. Mercato aperto.

GlobeNewswire
Sosei Heptares’ partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults
NBI-1117570 is an investigational, oral, muscarinic M1/M4 selective dual agonist discovered by Sosei Heptares that may have the potential to treat neurological and neuropsychiatric conditionsNBI-1117570 is the second compound to advance into clinical development from a portfolio of selective muscarinic receptor agonists licensed by Sosei Heptares to Neurocrine following NBI-1117568, an oral, selective muscarinic M4 receptor agonist, which is in Phase 2 clinical trials as an investigational treat